|
1
|
McGettrick AF and O'Neill LA: Toll-like
receptors: Key activators of leucocytes and regulator of
haematopoiesis. Br J Haematol. 139:185–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sada T, Ota M, Katsuyama Y, Meguro A,
Nomura E, Uemoto R, Nishide T, Okada E, Ohno S, Inoko H and Mizuki
N: Association analysis of Toll-like receptor 7 gene polymorphisms
and Behçet's disease in Japanese patients. Hum Immunol. 72:269–272.
2011. View Article : Google Scholar
|
|
3
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aspord C, Tramcourt L, Leloup C, Molens
JP, Leccia MT, Charles J and Plumas J: Imiquimod inhibits melanoma
development by promoting pDC cytotoxic functions and impeding tumor
vascularization. J Invest Dermatol. 134:2551–2561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diebold SS, Kaisho T, Hemmi H, Akira S and
Reis e Sousa C: Innate antiviral response by means of TLR7-mediated
recognition of single-stranded RNA. Science. 303:1529–1531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma F, Zhang J, Zhang J and Zhang C: The
TLR7 agonists imiquimod and gardiquimod improve DC-based
immunotherapy for melanoma in mice. Cell Mol Immunol. 7:381–388.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steele CW, Jamieson NB, Evans TR, McKay
CJ, Sansom OJ, Morton JP and Carter CR: Exploiting inflammation for
therapeutic gain in pancreatic cancer. Br J Cancer. 108:997–1003.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raimondi S, Maisonneuve P and Lowenfels
AB: Epidemiology of pancreatic cancer: An overview. Nat Rev
Gastroenterol Hepatol. 6:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Zhao J, Huang J, Tang H, Yu S and
Chen Y: The regulatory roles of miRNA and methylation on oncogene
and tumor suppressor gene expression in pancreatic cancer cells.
Biochem Biophys Res Commun. 425:51–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meager A, Heath A, Dilger P, Zoon K and
Wadhwa M; Participants of the Collaborative Study: Standardization
of human IL-29 (IFN-λ1): establishment of a World Health
Organization international reference reagent for IL-29 (IFN-λ1). J
Interferon Cytokine Res. 34:876–884. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koido S, Homma S, Takahara A, Namiki Y,
Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma
K, et al: Current immunotherapeutic approaches in pancreatic
cancer. Clin Dev Immunol. 2011:2675392011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A,
Takahashi H, Wakasugi T, Funahashi H, Sato M and Takeyama H: IGF-1
mediates PTEN suppression and enhances cell invasion and
proliferation via activation of the IGF-1/PI3K/Akt signaling
pathway in pancreatic cancer cells. J Surg Res. 60:90–101. 2010.
View Article : Google Scholar
|
|
14
|
Shi Y, Tong M, Wu Y, Yang Z, Hoffman RM,
Zhang Y, Tian Y, Qi M, Lin Y, Liu Y, et al: VEGF-C ShRNA inhibits
pancreatic cancer growth and lymphangiogenesis in an orthotopic
fluorescent nude mouse model. Anticancer Res. 33:409–417.
2013.PubMed/NCBI
|
|
15
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.
|
|
16
|
Lorente L, Martín MM, Solé-Violán J,
Blanquer J, Labarta L, Díaz C, Borreguero-León JM, Orbe J,
Rodríguez JA, Jiménez A and Páramo JA: Association of
sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio.
PLoS One. 9:e943182014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zampini R, Argañaraz ME, Miceli DC and
Apichela SA: Detection of the matrix metalloproteinases MMP-2 and
MMP-9 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2
in llama (Lama glama) oviduct. Reprod Domest Anim. 49:492–498.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fehres CM, Bruijns SC, van Beelen AJ,
Kalay H, Ambrosini M, Hooijberg E, Unger WW, de Gruijl TD and van
Kooyk Y: Topical rather than intradermal application of the TLR7
ligand imiquimod leads to human dermal dendritic cell maturation
and CD8+ T-cell cross-priming. Eur J Immunol. 44:2415–2424. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu X, Wang Y, Zhao W, Zhou H, Yang W and
Guan X: Toll-like receptor 7 promotes the apoptosis of
THP-1-derived macrophages through the CHOP-dependent pathway. Int J
Mol Med. 34:886–893. 2014.PubMed/NCBI
|
|
20
|
Ochi A, Graffeo CS, Zambirinis CP, Rehman
A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, et
al: Toll-like receptor 7 regulates pancreatic carcinogenesis in
mice and humans. J Clin Invest. 122:4118–4129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu J, Lai K, Brownile R, Babiuk LA and
Mutwiri GK: Porcine TLR8 and TLR7 are both activated by a selective
TLR7 ligand, imiquimod. Mol Immunol. 45:3238–3243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han JH, Park SY, Kim JB, Cho SD, Kim B,
Kim BY, Kang MJ, Kim DJ and Park JH and Park JH: TLR7 expression is
decreased during tumour progression in transgenic adenocarcinoma of
mouse prostate mice and its activation inhibits growth of prostate
cancer cells. Am J Reprod Immunol. 70:317–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Cheng FW, Wang F, Jia B, Luo X and
Zhang SQ: The activation of TLR7 regulates the expression of VEGF,
TIMP1, MMP2, IL-6 and IL-15 in Hela cells. Mol Cell Biochem.
389:43–49. 2014. View Article : Google Scholar
|
|
24
|
Medzhitov R, Preston-Hurlburt P and
Janeway CA Jr: A human homologue of the Drosophila Toll protein
signals activation of adaptive immunity. Nature. 388:394–397. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harvey RD and Morgan ET: Cancer,
inflammation, and therapy: Effects on cytochrome p450-mediated drug
metabolism and implications for novel immunotherapeutic agents.
Clin Pharmacol Ther. 96:449–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Cigliano A, Delogu S, Armbruster
J, Dombrowski F, Evert M, Chen X and Calvisi DF: Functional
crosstalk between AKT/mTOR and Ras/MAPK pathways in
hepatocarcinogenesis: Implications for the treatment of human liver
cancer. Cell Cycle. 12:1999–2010. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pivarcsi A, Müller A, Hippe A, Rieker J,
van Lierop A, Steinhoff M, Seeliger S, Kubitza R, Pippirs U, Meller
S, et al: Tumor immune escape by the loss of homeostatic chemokine
expression. Proc Natl Acad Sci USA. 104:19055–19060. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang HT, Cohen P and Rousseau S:
IL-1beta-stimulated activation of ERK1/2 and p38alpha MAPK mediates
the transcriptional up-regulation of IL-6, IL-8 and GRO-alpha in
HeLa cells. Cell Signal. 20:375–380. 2008. View Article : Google Scholar
|
|
30
|
Haydn JM, Hufnagel A, Grimm J, Maurus K,
Schartl M and Meierjohann S: The MAPK pathway as an apoptosis
enhancer in melanoma. Oncotarget. 5:5040–5053. 2014. View Article : Google Scholar : PubMed/NCBI
|
